The role of hepassocin in the development of non-alcoholic fatty liver disease

J Hepatol. 2013 Nov;59(5):1065-72. doi: 10.1016/j.jhep.2013.06.004. Epub 2013 Jun 18.

Abstract

Background & aims: While non-alcoholic fatty liver disease (NAFLD) is the most common risk factor of chronic liver disease, the mechanisms that initiate its development are obscure. Hepassocin (HPS) is a hepatokine that has been reported to be involved in liver regeneration. In addition to the mitogenic activity of HPS, HPS expression is decreased in patients with hepatoma. However, the role of HPS in NAFLD is still unknown.

Methods: A total of 393 subjects with (n=194) or without (n=199) NAFLD were enrolled to evaluate the serum HPS concentration. In order to clarify the causal inference between HPS and NAFLD, we used experimental animal and cell models. Hepatic overexpression or silencing of HPS was achieved by lentiviral vector delivery in mice and lipofectamine transfection in HepG2 cells. Lipogenesis related proteins were detected by Western blots. The expression of inflammatory factors was determined by real-time polymerase chain reaction.

Results: Subjects with NAFLD had a higher serum HPS concentration than those without it. Overexpression of HPS increased hepatic lipid accumulation and NAFLD activity scores (NAS), whereas deletion of HPS improved high fat diet-induced hepatic steatosis and decreased NAS in mice. Additionally, oleic acid, a steatogenic reagent, increased HPS expression in hepatocytes. Furthermore, overexpression of HPS in HepG2 cells induced lipid accumulation through an extracellular signal-regulated kinase 1/2 (ERK1/2)-dependent pathway, whereas deletion of HPS decreased oleic acid-induced lipid accumulation.

Conclusions: The present study provides evidence that HPS plays an important role in NAFLD and induces hepatic lipid accumulation through an ERK1/2-dependent pathway.

Keywords: ACC-1; ERK1/2; FAS; FFAs; Fatty acids; HCC; HFD; HNF-1; HPS; Hepatic steatosis; Liver; NAFLD; NAFLD activity score; NAS; NASH; OA; Oleic acid; SREBP-1; STAT3; acetyl-CoA carboxylase-1; extracellular signal-regulated kinase 1/2; fatty acid synthase; free fatty acids; hepassocin; hepatocellular carcinoma; hepatocyte nuclear factor-1; high fat diet; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; oleic acid; signal transducer and activator of transcription 3; sterol regulatory element-binding protein-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Animals
  • Case-Control Studies
  • Cells, Cultured
  • Diet, High-Fat / adverse effects
  • Disease Models, Animal
  • Fatty Liver / metabolism*
  • Fatty Liver / pathology
  • Fatty Liver / physiopathology*
  • Female
  • Fibrinogen / genetics
  • Fibrinogen / physiology*
  • Gene Deletion
  • Hep G2 Cells
  • Hepatocytes / drug effects
  • Hepatocytes / metabolism
  • Hepatocytes / pathology
  • Humans
  • Lipid Metabolism / drug effects
  • Lipid Metabolism / physiology*
  • MAP Kinase Signaling System / drug effects
  • MAP Kinase Signaling System / physiology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Middle Aged
  • Neoplasm Proteins / blood
  • Neoplasm Proteins / physiology*
  • Non-alcoholic Fatty Liver Disease
  • Oleic Acid / pharmacology

Substances

  • FGL1 protein, human
  • Fgl1 protein, mouse
  • Neoplasm Proteins
  • Oleic Acid
  • Fibrinogen